PCM
KROS icon

Penserra Capital Management’s Keros Therapeutics KROS Stock Holding History

Penserra Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,839
Closed -$383K – 1147
2025
Q4 		$383K Buy
+18,839
New +$331K ﹤0.01% 572
2021
Q4 		– Sell
-535
Closed -$21K – 1459
2021
Q3 		$21K Buy
535
+5
+0.9% +$178 ﹤0.01% 1237
2021
Q2 		$22K Buy
530
+10
+2% +$542 ﹤0.01% 1126
2021
Q1 		$32K Sell
520
-10
-2% -$634 ﹤0.01% 891
2020
Q4 		$37K Buy
+530
New +$33.4K ﹤0.01% 740

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Penserra Capital Management's KROS Position: Q1 2026 in Review

Penserra Capital Management sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 18,839 shares — an estimated $383K sold.

Penserra Capital Management first reported a position in KROS in Q4 2020 and held it in 5 quarters. The position peaked at $383K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Penserra Capital Management reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 18,839 Keros Therapeutics shares in Q1 2026, an estimated $383K.
  • Penserra Capital Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 5 quarters.
  • Penserra Capital Management's Keros Therapeutics position peaked at $383K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.